Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine (129 page)

leukostasis, 5-17

Libman-Sacks endocarditis, 8-15

Liddle’s syndrome, 4-5, 4-10, 7-8

Light’s criteria, 2-11

limb ischemia, acute, 1-41, 10-1

lipodystrophy, 6-19

liver failure, 3-20

liver tests, abnormal, 3-15

liver transplantation, 3-23

Loeys-Dietz syndrome, 1-31

Löffler’s endocarditis, 1-19

Löffler’s syndrome, 2-10

Löfgren’s syndrome, 2-9

long QT syndrome, 1-34

lung cancer, 5-28

lupus anticoagulant, 5-11

lupus pernio, 2-9

Lyme disease, 6-20

lymphadenopathy, 5-12

lymphangioleiomyomatosis, 2-10

lymphocytic interstitial pneumonia, 2-10

lymphocytosis, 5-12

lymphoma, 5-21

CNS, 6-19

Hodgkin, 5-21

non-Hodgkin, 5-22

M

macro-ovalocytes, 5-3

malabsorption, 3-6

malaria, 6-23

Mallory-Weiss tear, 3-3

mammography, 5-30

Marfan syndrome, 1-31

mechanical ventilation, 2-19

mechanic’s hands, 8-13

Meckel’s diverticulum, 3-4

Meigs’ syndrome, 2-11, 3-26

MELD score, 3-23

melena, 3-3

membranoproliferative glomerulonephritis, 4-17

membranous nephropathy, 4-17

meningitis

acute bacterial, 6-9

aseptic, 6-10

mental status, change in, 9-1

mesenteric ischemia, 3-12

metabolic acidosis, 4-2

metabolic alkalosis, 4-4

metabolic syndrome, 7-16

methanol intoxication, 4-2

methemoglobinemia, 2-18

microangiopathic hemolytic anemia, 5-5

microscopic polyangiitis, 8-19

as cause of glomerulonephritis, 4-16

as cause of interstitial lung disease, 2-10

migraine headache, 9-10

milk-alkali syndrome, 7-11

minimal change disease, 4-17

Mirizzi’s syndrome, 3-27

mitral regurgitation, 1-22

mitral stenosis, 1-22

mitral valve prolapse, 1-23

mixed connective tissue disease (MCTD), 8-14

molluscum contagiosum, 6-18

monoclonal gammopathy of uncertain significance, 5-25

monocytosis, 5-12

mucinous cystic neoplasm of pancreas, 5-35

Mucor
infection, 6-4

multiple endocrine neoplasia (MEN) syndromes, 7-2

multiple myeloma, 5-24

murmurs, eponymous

Austin Flint, 1-21

Graham Steel, 2-14

Murphy’s sign, 3-27

myalgias, 8-13

myasthenia gravis, 9-9

Mycobacterium avium
complex, disseminated, 6-19

mycosis fungoides, 5-22

myelodysplastic syndromes, 5-14

myelofibrosis, primary, 5-16

myeloid neoplasms, 5-14

myeloproliferative neoplasms, 5-15

myocardial infarction (MI)

non ST elevation, 1-7

ST elevation, 1-9

myocardial viability, 1-4

myocarditis, 1-3, 1-17

myopathies, 8-12, 9-9

myositides, 8-13

myxedema, 7-4

N

necrotizing fasciitis, 6-7

nephrogenic systemic fibrosis, 4-12

nephrolithiasis, 4-19

nephrotic syndrome, 4-17

nerve root compression, 9-11

neuropathies, 9-8

neutropenia, 5-12, 5-36, 6-4

neutropenic enterocolitis, 5-36

neutrophilia, 5-12

New York Heart Association classification, 1-14

nonalcoholic fatty liver disease (NAFLD), 3-19

noninvasive ventilation, 2-20

nonspecific interstitial pneumonia, 2-10

nonulcer dyspepsia, 3-2

nutrition, in hospitalized, 3-8

O

obstructive sleep apnea, 2-8

ocular motor palsies, 10-4

oculocephalic maneuver, 9-1

Ogilvie’s syndrome, 3-8

omega-3 fatty acids, 1-16, 7-16

optic neuritis, 10-4

optic neuropathy, ischemic, 10-4

oral hairy leukoplakia, 6-18

orbital cellulitis, 10-4

orthostatic hypotension, 1-37

Osler’s nodes, 6-12

osmolal gap, 4-3, 11-6

osteoarthritis, 8-1, 8-2

osteomyelitis, 6-8

P

pacemakers, 1-39

Paget’s disease

of bone, 7-11

of breast, 5-30

Pancoast’s syndrome, 5-28

pancreatic cancer, 5-35

pancreatic insufficiency, 3-7

pancreatitis, 3-13

pancytopenia, 5-3

panhypopituitarism, 7-1

papillary muscle rupture, 1-10

Pappenheimer bodies, 5-2

paracentesis, 3-26

paroxysmal nocturnal syndromes, 5-4

patent foramen ovale, 9-7

peptic ulcer disease (PUD), 1-3, 3-2

percutaneous coronary intervention (PCI), 1-5

pericardial effusion, 1-25

pericardial tamponade, 1-26

pericarditis, 1-25

periodic paralysis

hyperkalemic, 4-11

hypokalemic, 4-10

peripheral smear, findings in, 11-6

peritoneal dialysis, 4-15

peritonitis, 3-26

petechiae, 5-6

pheochromocytoma, 7-10

phlegmasia cerulean dolens, 2-13

pica, 5-1

pituitary disorders, 7-1

pituitary tumors, 7-1

plasma cell dyscrasias, 5-24

platelet disorders, 5-7

pleural effusion, 2-11, P-4

pleuritis, 1-3

Plummer-Vinson syndrome, 5-1

pneumoconioses, 2-10

pneumocystis, 2-10

Pneumocystis jiroveci
pneumonia, 6-19

pneumonia, 6-1, P-2

pneumothorax, P-4

POEMS syndrome, 5-24

polyarteritis nodosa, 8-18

polycythemia vera, 5-15

polydipsia, 4-9

polyglandular autoimmune (PGA) syndromes, 7-2

polymyalgia rheumatica, 8-13, 8-18

polymyositis, 8-12

polyuria, 4-9

porphyria cutanea tarda, 3-18

portal hypertension, 3-21

portal vein thrombosis (PVT), 3-25

portopulmonary hypertension, 2-16, 3-23

portosystemic encephalopathy, 3-22

Pott’s disease, 6-8, 6-15

preexcitation, 1-33

pregnancy, ectopic, 10-3

preoperative risk assessment, 1-40

prerenal azotemia, 4-12

primary biliary cirrhosis, 3-24

primary sclerosing cholangitis, 3-24

Prinzmetal’s angina, 1-6

progressive multifocal leukencephalopathy, 6-19

prolactinoma, 7-1

propylene glycol intoxication, 4-2

prostate cancer, 5-32

prostate-specific antigen (PSA) testing, 5-32

prostatitis, 6-5

prosthetic heart valves, 1-24

proteinuria, 4-18

prothrombin mutation, 5-11

pseudogout, 8-6

pseudo-hypoparathyroidism, 7-12

pseudo-Pelger-Huët cells, 5-14, 11-6

pseudotumor cerebri, 9-10

pulmonary alveolar proteinosis, 2-10

pulmonary artery catheter, 1-12, 11-4

pulmonary edema

CXR pattern in, 11-5, P-2

treatment of, 1-15, 11-2

pulmonary embolism, 2-14, P-6

pulmonary function tests, 2-1

pulmonary hypertension, 2-16

pulseless electrical activity, ACLS-2

pulsus paradoxus, 1-26

pure red cell aplasia, 5-2

purified protein derivative (PPD) test, 6-15

purpura, 5-6

pyelonephritis, 6-5

pyoderma gangrenosum, 3-10, 8-8

Q

QT interval, 1-1

R

radiculopathies, 9-11

radioactive iodine uptake scan, 7-3

Raynaud’s phenomenon, 8-14

red eye, 10-4

Reed-Sternberg cells, 5-21

refeeding syndrome, 3-8

Reiter’s syndrome, 8-7

relapsing polychondritis, 8-4

renal abscess, 6-5

renal artery stenosis, 1-28

renal failure, 4-12

renal osteodystrophy, 7-12

renal replacement therapy, 4-15

renal tubular acidosis, 4-3

respiratory acidosis, 4-5

respiratory alkalosis, 4-5

respiratory bronchiolitis-associated interstitial lung disease, 2-10

respiratory failure, 2-18

reticulocyte index, 5-1

Reynold’s pentad, 3-28

rheumatoid factor, 8-3

Rhizopus
infection, 6-4

Richter’s syndrome, 5-20

Rocky Mountain spotted tick fever, 6-21

Roth spots, 6-12

S

salicylate intoxication, 4-2

Samter’s syndrome, 2-2

sarcoidosis, 2-9, P-6

cardiac manifestations of, 1-19

schistocytes, 5-5, 11-6, P-14

sciatica, 9-11

scleroderma, 8-11

seizures, 9-3

sepsis, 2-23

seronegative spondyloarthritis, 8-7

serum-ascites albumin gradient, 3-26

Sézary syndrome, 5-22

Sheehan’s syndrome, 7-1

shock, 1-13, 11-2

cardiogenic, 1-13

septic, 2-23

sicca syndrome, 8-13

sick euthyroid syndrome, 7-5

sick sinus syndrome, 1-32

silicosis, 2-10

sinusoidal obstruction syndrome, 3-25, 5-26

Sjögren’s syndrome, 8-13

smudge cells, 5-20

soft tissue infections, 6-6

solitary pulmonary nodule, 2-8

spinal cord compression, 5-36, 9-11

spinal stenosis, 9-12

splenomegaly, 5-5

spontaneous bacterial peritonitis, 3-26

treatment of in cirrhosis, 3-22

spur cells, 11-6, P-14